Health Systems and COVID-19 Michael Hochman, MD, MPH Gehr Family - - PowerPoint PPT Presentation

▶
health systems and covid 19
SMART_READER_LITE
LIVE PREVIEW

Health Systems and COVID-19 Michael Hochman, MD, MPH Gehr Family - - PowerPoint PPT Presentation

Aug 02, 2023 210 likes •495 views

Health Systems and COVID-19 Michael Hochman, MD, MPH Gehr Family Center for Health Systems Science & Innovation April 13, 2020 Agenda Overview of Health System Approaches via the Keck Medicine of USC Lens 2 Norbert Gehr and David

slide-1
SLIDE 1

Health Systems and COVID-19

Michael Hochman, MD, MPH Gehr Family Center for Health Systems Science & Innovation April 13, 2020

slide-2
SLIDE 2
  • Overview of Health System Approaches

via the Keck Medicine of USC Lens

Agenda

2

slide-3
SLIDE 3

Norbert Gehr and David Goldstein

3

slide-4
SLIDE 4
  • How does SARS-CoV-2 spread?

Protecting Healthcare Workers

4

slide-5
SLIDE 5
  • Deep cleaning
  • Patient and healthcare worker wear masks

Protecting Healthcare Workers

5

slide-6
SLIDE 6
  • For aerosolizing procedures

N95s

6

slide-7
SLIDE 7
  • 65+
  • Chronic conditions
  • Pregnancy

High Risk Employees

7

slide-8
SLIDE 8

Triage System

8

slide-9
SLIDE 9

Telemedicine

9

slide-10
SLIDE 10

Telemedicine

10

slide-11
SLIDE 11

Telemedicine

11

slide-12
SLIDE 12

Telemedicine

12

slide-13
SLIDE 13

Testing

13

slide-14
SLIDE 14
  • Therapeutic Purposes:
  • Critically ill patients
  • Public Health Purposes:
  • Self-isolation
  • Contact tracing

Testing

14

slide-15
SLIDE 15

Evidence-Based Treatment

15

slide-16
SLIDE 16

ICU Care

16

slide-17
SLIDE 17

“While there is pressure to fast-track the evaluation of COVID-19 treatment, adherence to rigorous scientific methods to evaluate potential COVID-19 therapies remains just as critical as ever to avoid unintended consequences. Taking “short-cuts” in the evaluation of new therapies may lead to widespread use of ineffective treatments with associated safety concerns.”

Principles

17

slide-18
SLIDE 18

“Some political advocacy groups are promoting “right to try” policies to enable patients to access unapproved and “off-label” therapies for COVID- 19 before rigorous evaluation. Prior experience has shown that that practices can cause more harm than good. Our team favors reserving experimental therapies for research settings. “Right to try” policies risks exposing patients to safety concerns without offering them benefits.”

Principles

18

slide-19
SLIDE 19

“The FDA has authorized an emergency use approval for hydroxychloroquine, however debate remains about whether the benefits outweigh the

  • risks. In one small randomized trial,

hydroxychloroquine failed to hasten clinical recovery

  • vs. control patients, however in another

hydroxychloroquine led to modestly faster clinical recovery, and lower rates of radiological pneumonia. Neither trial has been peer reviewed.“

Hydroxychloroquine

19

slide-20
SLIDE 20

Advanced Care Planning

20

slide-21
SLIDE 21

“As COVID-19 infection and morbidity rates peak in the U.S., experts have begun suggesting validated approaches -- such as “suppress and lift” policies, “targeted approaches” and immunity testing -- as well as criteria for cautiously easing social and economic restrictions without triggering sudden and dramatic recurrences of disease spread that could

  • verwhelm the healthcare system.“

Easing of Social Distancing

21

slide-22
SLIDE 22

Contact Tracing

22

slide-23
SLIDE 23

Digital Contact Tracing

23

slide-24
SLIDE 24

Keck Evidence-Based COVID Resource

24

Keck.usc.edu/coronavirus/

slide-25
SLIDE 25

Gehr-Akido-AltaMed COVID Self- Assessment Tool

25

Covidassessment.org

slide-26
SLIDE 26

Gehr-Akido-AltaMed COVID Self- Assessment Tool

26

slide-27
SLIDE 27

Gehr-Akido-AltaMed COVID Self- Assessment Tool

27

slide-28
SLIDE 28
  • Questions?

Speaker Contact: mhochman@usc.edu

Thank you

28